These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 11353778)
1. Targeted toxins begin to live up to early expectations. Thompson T J Natl Cancer Inst; 2001 May; 93(10):736-8. PubMed ID: 11353778 [No Abstract] [Full Text] [Related]
2. A magic bullet for cancer--how near and how far? Schnipper LE; Strom TB N Engl J Med; 2001 Jul; 345(4):283-4. PubMed ID: 11474668 [No Abstract] [Full Text] [Related]
3. Treatment of hairy-cell leukemia. Saven A N Engl J Med; 2001 Nov; 345(20):1500-1. PubMed ID: 11794207 [No Abstract] [Full Text] [Related]
4. Recombinant toxins for the treatment of cancer. Kreitman RJ Curr Opin Mol Ther; 2003 Feb; 5(1):44-51. PubMed ID: 12669470 [TBL] [Abstract][Full Text] [Related]
5. Immunotoxins in cancer therapy: Review and update. Akbari B; Farajnia S; Ahdi Khosroshahi S; Safari F; Yousefi M; Dariushnejad H; Rahbarnia L Int Rev Immunol; 2017 Jul; 36(4):207-219. PubMed ID: 28282218 [TBL] [Abstract][Full Text] [Related]
6. First responses seen in cancer patients to a recombinant immunotoxin. Kuska B J Natl Cancer Inst; 1999 Dec; 91(23):1997. PubMed ID: 10580021 [No Abstract] [Full Text] [Related]
14. Rationale for the clinical use of immunotoxins: monoclonal antibodies conjugated to ribosome-inactivating proteins. Preijers FW Leuk Lymphoma; 1993 Mar; 9(4-5):293-304. PubMed ID: 8348066 [TBL] [Abstract][Full Text] [Related]
15. Alpha interferons in hairy cell leukaemia: a clinical model of biological therapy for cancer. Quesada JR Interferon; 1987; 8():111-34. PubMed ID: 3316039 [No Abstract] [Full Text] [Related]
16. Human toxin-based recombinant immunotoxins/chimeric proteins as a drug delivery system for targeted treatment of human diseases. Lorberboum-Galski H Expert Opin Drug Deliv; 2011 May; 8(5):605-21. PubMed ID: 21453191 [TBL] [Abstract][Full Text] [Related]
17. Targeted delivery of toxins and enzymes by antibodies and growth factors. Houston LL Curr Opin Biotechnol; 1993 Dec; 4(6):739-44. PubMed ID: 7764474 [TBL] [Abstract][Full Text] [Related]
18. Potential breakthroughs with investigational drugs for hairy cell leukemia. Robak T; Wolska A; Robak P Expert Opin Investig Drugs; 2015; 24(11):1419-31. PubMed ID: 26329588 [TBL] [Abstract][Full Text] [Related]
19. Historical overview of hairy cell leukemia. Andritsos LA; Grever MR Best Pract Res Clin Haematol; 2015 Dec; 28(4):166-74. PubMed ID: 26614894 [TBL] [Abstract][Full Text] [Related]
20. Recombinant antibody fragments and immunotoxin fusions for cancer therapy. Brinkmann U In Vivo; 2000; 14(1):21-7. PubMed ID: 10757057 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]